Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial

Document Details

Document Type
Pub Defense Publication
Publication Date
Jan 01, 2021
Source ID
10.1016/s0140-6736(20)32554-x

Entities

People

  • Alexander B Olawaiye
  • Amit M. Oza
  • Andrea E. Wahner Hendrickson
  • Charles A Kunos
  • Eric Chen
  • Gemma N Jones
  • Gina Mantia-smaldone
  • Gini F. Fleming
  • Jaime Rodriguez-canales
  • Jeffrey P Bruce
  • Johanne I Weberpals
  • Katherine Karakasis
  • Lisa Wang
  • Michael Cabanero
  • Michael Tracy
  • Mihaela C. Cristea
  • Neesha C. Dhani
  • Prisni Rath
  • Qian Tan
  • Smitha Udagani
  • Stephanie Lheureux
  • Stephen R Welch
  • Susan L Ellard
  • Suzanne Jenkins
  • Swati Garg
  • Tracy Stockley
  • Trevor J Pugh
  • Valerie Bowering

Organizations

  • National Cancer Institute
  • Ontario Institute for Cancer Research
  • United States Department of Defense